

December 12, 2019



SCYNEXIS Announces Closing of \$35 Million Public Offering of Common Stock and Warrants

JERSEY CITY, N.J., Dec. 12, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ : SCYX) today announced the closing of its previously announced underwritten public offering of 38,888,889 shares of common stock and warrants to purchase up to 38,888,889 shares of common stock. Each share of common stock and warrant to purchase one share of common stock were sold at a combined public offering price of \$0.90 per share and accompanying warrant. The total gross proceeds to SCYNEXIS from this offering were approximately \$35 million, including the exercise of the underwriters' option to purchase additional warrants, before deducting underwriting discounts and commissions and other estimated offering expenses, and excluding the exercise of any warrants. All of the shares of common stock and warrants were offered by SCYNEXIS.

H.C. Wainwright & Co. acted as sole book-running manager for the offering. Aegis Capital Corp., Brookline Capital Markets, a division of Arcadia Securities, LLC, Maxim Group LLC and WBB Securities acted as the co-managers for the offering.

The warrants have an exercise price of \$1.10 per share and exercise period commencing immediately upon issuance and an expiration date of the earlier of (i) such date that is six months after SCYNEXIS publicly announces the approval from the U.S. Food and Drug Administration for ibrexafungerp for the treatment of vulvovaginal candidiasis and (ii) June 12, 2023. There is no established public trading market for the warrants, and SCYNEXIS does not expect a market to develop.

A shelf registration statement relating to the securities being sold in this offering was filed with the U.S. Securities and Exchange Commission (SEC) on August 31, 2018, and was declared effective on September 14, 2018. The offering is being made only by means of a prospectus supplement and accompanying prospectus. A final prospectus supplement and accompanying prospectus relating to the offering were filed with the SEC and are available for free on the SEC's website located at <http://www.sec.gov>. When available, electronic copies of the final prospectus supplement and accompanying prospectus relating to the public offering may be obtained by contacting H.C. Wainwright & Co., LLC, 430 Park Avenue, 3rd Floor, New York, NY 10022, or by telephone at (646) 975-6996, or by email to placements@hcwco.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About SCYNEXIS

SCYNEXIS is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, having discovered and developed more than 30 innovative medicines over a broad range of therapeutic areas. SCYNEXIS's lead product candidate, ibrexafungerp (formerly known as SCY-078), is a novel IV/oral antifungal agent in Phase 3 clinical and preclinical development for the treatment of multiple serious and life-threatening invasive fungal infections caused by *Candida*, *Aspergillus* and *Pneumocystis* species.

Forward-Looking Statements

This announcement contains forward-looking statements, including statements relating to SCYNEXIS's expectations regarding the public offering. These statements are subject to significant risks and uncertainties and actual results could differ materially from those projected. SCYNEXIS cautions investors not to place undue reliance on the forward-looking statements contained in this release. These risks and uncertainties include, without limitation, risks and uncertainties related to market conditions. Risks and uncertainties relating to SCYNEXIS and its business can be found in the "Risk Factors" section of SCYNEXIS's Form 10-K for the year ended December 31, 2018, filed with the SEC on March 14, 2019, in the "Risk Factors" section of SCYNEXIS's Form 10-Q for the quarter ended September 30, 2019, filed with the SEC on November 12, 2019, and in the final prospectus supplement contained in the registration statement related to the public offering filed with the SEC on December 11, 2019. SCYNEXIS undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in SCYNEXIS's expectations, except as required by law.

Investor Relations

Heather Savelle
Argot Partners
Tel: 212-600-1902
heather@argotpartners.com

Media Relations

George E. MacDougall
MacDougall
Tel: 781-235-3093
george@macbiocom.com

View original content: <http://www.prnewswire.com/news-releases/scynexis-announces-closing-of-35-million-public-offering-of-common-stock-and-warrants-300974221.html>

SOURCE SCYNEXIS, Inc.